New data support tailoring regional nodal irradiation in patients treated with neoadjuvant chemotherapy on the basis of their ...

At a past Power Athlete event, former Navy SEAL and seasoned speaker Andy Stumpf delivered a sharp, no-nonsense lesson on goal setting that cut through the fluf ...

The risk of recurrence was generally low among cervical cancer patients with no high-risk factors who underwent radical surgery without adjuvant therapy.

ERC Advanced Grants worth a total of €721m were awarded to 281 researchers, with UCD's Prof Kylie Jarrett and Dr Barry Wardell among the winners.

Phase 2 trial results support Isa-KRd as a standard treatment option for patients with high-risk, newly diagnosed multiple myeloma, according to researchers.

The estimated risk ratio (RR) was 1.29 (95% CI 1.05 to 1.59 ... It is worth noting that our research team previously conducted a review that encompassed data until 2016.9 Considering the current ...

Oesophageal adenocarcinoma has an extremely poor prognosis, and improving outcomes via therapy remains particularly challenging in such a heterogeneous cancer. Another avenue for improving outcomes ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Despite calls from some corners to switch from canola oil and corn oil to beef tallow, the move is unlikely to make Americans healthier.

How AI, regulatory reform, and cultural diversity could help European startups challenge Silicon Valley's dominance.

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

That being said, we’re here with a list of the 9 best inexpensive stocks to buy right now. We used the Finviz stock screener to compile a list of the top stocks with a forward P/E ratio of 20 or less, ...